Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience

Karadayi K., Yildiz C., Karakus S., Akkar O. B., Ugurlu G. P., Kurt A., ...Daha Fazla

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, cilt.37, sa.2, ss.194-198, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.12892/ejgo2786.2016
  • Dergi Adı: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.194-198
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Introduction: The objective of this study was to assess the outcome of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) plus early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gynecological malignancies. Materials and Methods: A retrospective series of 51 patients with advanced gynecologic cancer, evaluated between May 2008 to February 2014. Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CCR) score were used in the study group. The study group consisted of the cancers of ovarian, fallopian tube, endometrial, and uterine sarcomas. Results: Mean PCI score of the study group was 18, and the postoperative complications were similar with the literature. Patients were followed in a period of 15 days to 64 months and the mean survival time was 22.8 months. Fifty-two percent of the patients were alive without evidence of the disease and overall one-year survival was found 56%. Conclusions: The authors concluded that CRS, HIPEC, EPIC, and peritonectomy are a crucial options in patients with advanced gynecological cancers.